| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, Texas and 2 Department of Bioimmunotherapy, Section of Immunopharmacology and Targeted Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Requests for reprints: Matthew Levy, Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX 78712. Phone: 512-471-6445; Fax: 512-471-7014; E-mail: mattlevy{at}mail.utexas.edu.
We have used RNA aptamer:gelonin conjugates to target and specifically destroy cells overexpressing the known cancer biomarker prostate-specific membrane antigen (PSMA). Aptamer:toxin conjugates have an IC50 of 27 nmol/L and display an increased potency of at least 600-fold relative to cells that do not express PSMA. The aptamer not only promotes uptake into target cells but also decreases the toxicity of gelonin in non-target cells. These results validate the notion that "escort aptamers" may be useful for the treatment of specific tumors expressing unique antigen targets.(Cancer Res 2006; 66(12): 5989-92)
This article has been cited by other articles:
|
|
 |
|
  J. Zhou, P. Swiderski, H. Li, J. Zhang, C. P. Neff, R. Akkina, and J. J. Rossi Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells Nucleic Acids Res., May 1, 2009; 37(9): 3094 - 3109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-h. B. Chen, K. R. Dellamaggiore, C. P. Ouellette, C. D. Sedano, M. Lizadjohry, G. A. Chernis, M. Gonzales, F. E. Baltasar, A. L. Fan, R. Myerowitz, et al. Aptamer-based endocytosis of a lysosomal enzyme PNAS, October 14, 2008; 105(41): 15908 - 15913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Martinez-Torrecuadrada, L. H. Cheung, P. Lopez-Serra, R. Barderas, M. Canamero, S. Ferreiro, M. G. Rosenblum, and J. I. Casal Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis Mol. Cancer Ther., April 1, 2008; 7(4): 862 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gu, L. Zhang, B. A. Teply, N. Mann, A. Wang, A. F. Radovic-Moreno, R. Langer, and O. C. Farokhzad From the Cover: Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers PNAS, February 19, 2008; 105(7): 2586 - 2591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ma and D. J. Waxman Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment Mol. Cancer Ther., November 1, 2007; 6(11): 2879 - 2890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rege, S. J. Patel, Z. Megeed, and M. L. Yarmush Amphipathic Peptide-Based Fusion Peptides and Immunoconjugates for the Targeted Ablation of Prostate Cancer Cells Cancer Res., July 1, 2007; 67(13): 6368 - 6375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Ellington, J. Ebright, T. Chu, and M. Levy Using Aptamers for Cell-Specific Labeling and Delivery Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 51 - 55. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C.B. Gopinath, D. Balasundaresan, J. Akitomi, and H. Mizuno An RNA Aptamer That Discriminates Bovine Factor IX from Human Factor IX J. Biochem., November 1, 2006; 140(5): 667 - 676. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
